<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the present study, we have isolated CD4+ CTLs that recognize an <z:chebi fb="0" ids="53000">epitope</z:chebi> from EBV nuclear Ag 2 in association with two different HLA-DQ Ags, DQA1*0501/DQB1*0201 (DQ2) or DQA1*0501/DQB1*0301 (DQ7) </plain></SENT>
<SENT sid="1" pm="."><plain>Both the HLA-DQ2 and HLA-DQ7 alleles displayed a similar efficiency in the endogenous and exogenous presentation of this <z:chebi fb="0" ids="53000">epitope</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Since earlier studies have shown that the EBV-associated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), escapes class I-restricted immune recognition by down-regulating the expression of <z:chebi fb="7" ids="16670">peptide</z:chebi> transporter genes, we have explored the possibility that these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells can process class II-restricted CTL <z:chebi fb="0" ids="53000">epitopes</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>The data presented in this study clearly demonstrate that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells were recognized efficiently by CD4+, MHC class II-restricted EBV-specific CTLs following <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> with recombinant <z:e sem="disease" ids="C0042214" disease_type="Disease or Syndrome" abbrv="">vaccinia</z:e> encoding EBV nuclear Ag 2 </plain></SENT>
<SENT sid="4" pm="."><plain>Analysis of surface MHC class II expression on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells revealed high levels of HLA-DR and HLA-DQ molecules, and most of these molecules were negative for the invariant chain <z:chebi fb="7" ids="16670">peptide</z:chebi>, referred to as CLIP </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells also showed <z:mpath ids='MPATH_458'>normal</z:mpath> levels of HLA-DMB gene expression, which has been shown previously to be an essential component of the class II processing pathway </plain></SENT>
<SENT sid="6" pm="."><plain>The present finding of efficient processing function through the class II pathway in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells provides a novel mechanism for immune targeting of EBV-positive <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>